Welcome to our dedicated page for Passage Bio news (Ticker: $PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Passage Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Passage Bio's position in the market.
Passage Bio (NASDAQ: PASG) reported its Q1 2024 financial results and provided business updates, including advances in its global upliFT-D clinical trial for FTD-GRN. The trial's Dose 1 PBFT02 consistently elevated CSF progranulin at six months in two patients. All five patients in Cohort 1 have been dosed, with safety and biomarker data expected in 2H 2024. Cohort 2 dosing is planned to start by the end of 1H 2024. The company initiated discussions with the FDA for using PBFT02 to treat FTD-C9orf72, with feedback expected in 2H 2024. Financially, the company ended Q1 with $104.5 million in cash, projecting a cash runway into Q4 2025. Net loss decreased to $16.7 million from $34.3 million year-over-year.